Rothschild & Co Asset Management US’s Vertex Pharmaceuticals VRTX Stock Holding History

Rothschild & Co Asset Management US’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-15,686	Closed	-$3.16M	–	281
2021 Q2	$3.16M	Sell	15,686 -1,309	-8%	-$274K	0.04%	233
2021 Q1	$3.65M	Sell	16,995 -734	-4%	-$161K	0.05%	233
2020 Q4	$4.19M	Buy	17,729 +1,191	+7%	+$273K	0.05%	237
2020 Q3	$4.5M	Sell	16,538 -27,938	-63%	-$7.71M	0.08%	243
2020 Q2	$12.9M	Sell	44,476 -19,983	-31%	-$5.42M	0.19%	191
2020 Q1	$15.3M	Sell	64,459 -3,931	-6%	-$902K	0.24%	161
2019 Q4	$15M	Sell	68,390 -816	-1%	-$165K	0.16%	221
2019 Q3	$11.7M	Sell	69,206 -2,782	-4%	-$492K	0.13%	247
2019 Q2	$13.2M	Buy	+71,988	New	+$12.6M	0.14%	225

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Rothschild & Co Asset Management US's VRTX Position: Q3 2021 in Review

Rothschild & Co Asset Management US sold out of Vertex Pharmaceuticals (VRTX) in Q3 2021, closing a stake of 15,686 shares — an estimated $3.16M sold.

Rothschild & Co Asset Management US first reported a position in VRTX in Q2 2019 and held it in 9 quarters. The position peaked at $15.3M in Q1 2020. 933 funds tracked by Wall St. Rank hold VRTX as of Q3 2021.

Rothschild & Co Asset Management US reported no remaining Vertex Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Rothschild & Co Asset Management US sold 15,686 Vertex Pharmaceuticals shares in Q3 2021, an estimated $3.16M.
Rothschild & Co Asset Management US first reported a position in Vertex Pharmaceuticals in Q2 2019 and held it in 9 quarters.
Rothschild & Co Asset Management US's Vertex Pharmaceuticals position peaked at $15.3M in Q1 2020.
933 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2021.

Based on Rothschild & Co Asset Management US's 13F filing for Q3 2021, filed 9 Nov 2021.